Skin analysisA HealthThek company focuses on the future creating “No one dies in skin cancer”, as well as in Europe and Australia, as well as the Intertipid Growth Partners, led by Series B Funds, has earned $ 17.5 million.
This investment is followed by the recent EU MDR Class III CE Mark approval of the skin analysis, it produces its technology, the derm, the world’s first legally approved AI medical device is independently approved to make clinical decisions on skin cancer without human review.
Blue DeliFounder and CEO of Skin Analytics says: “AI lets our experts go from the world to one where we have the ability to see everyone concerned about our skin. Starting with skin cancer, this fund allows our partners to work to create new models that everyone can access whenever they access. It brings us closer to the world where no one dies in skin cancerThe
“We have proved this technology in the UK and now it’s available worldwide it is availableThe “
Established by Blue Daley in 2012, Skin Analytics began supply to the Teledestology Service in 2015 and has now been deployed to 26 NHS sites across the UK since 2020. According to statistics provided by skin analysis, they consult more than 150,000 NHS patients and have detected more than 14,000 cancer. Surveillance after the market has shown that Derm 98.9%found 97%cancer with a negative prophetic value (NPV) of 99.8%compared to the dermatologist evaluation.
It has been reported that up to 40% of the referrals of the cancer of the derm autonomously suspected skin cancer can be autonomously discharge. The settings that have been deployed in the derm have been able to reduce the number of appointments in the face-to-face dermatologist by 60-95%required for the amount of suspected skin cancer referrals.
The investment is a few months waiting for the worldwide healthcare systems worldwide under unprecedented dermatologists deficit. About the average 30 dermatologists per 30 million population In Europe, practitioners deficiency is completely considered when the skin-related problems are consistently rank in the top 10 reasons to see the elementary doctor-according to analysis.
Mark machineThe Co-founder and Managing Partner of Intripid Growth Partners commented: “In Intripid Growth Partners, we invest in converting machine detective-powered solutions that solve critical challenges and skin analyzes give examples of this aspect. Their technology is defining primary skin cancer detection, improving the patient’s results while reducing health care costs. We are eager to support their growth as they make their impact worldwideThe “
Deli Connected: “It’s simply the beginning. AI will allow our patients to renew healthcare systems around the world for the convenience of our patients. The faster we scale, the more we can influence life. That mission drives us every day.“
[publish_date
